20. 副腎白質ジストロフィー Adrenoleukodystrophy Clinical trials / Disease details
臨床試験数 : 53 / 薬物数 : 88 - (DrugBank : 31) / 標的遺伝子数 : 23 - 標的パスウェイ数 : 123
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03196765 (ClinicalTrials.gov) | August 2018 | 5/5/2017 | Safety, Pharmacokinetics and Pharmacodynamics of NV1205 in Pediatric Male Subjects With Adrenoleukodystrophy | Phase I/II, Open-Label, Dose Escalation Study of the Safety, Pharmacokinetics and Pharmacodynamics of NV1205 in Pediatric Male Subjects With Childhood Cerebral Adrenoleukodystrophy (CCALD) | X-Linked Adrenoleukodystrophy | Drug: Sobetirome (NV1205) | NeuroVia, Inc. | NULL | Withdrawn | 4 Years | 18 Years | Male | 0 | Phase 1/Phase 2 | Argentina;Australia;Chile;Colombia;France;Russian Federation;Ukraine;United Kingdom |
| 2 | EUCTR2017-001684-21-GB (EUCTR) | 20/04/2018 | 26/10/2017 | Phase I/II, Open-Label, Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of NV1205 in Pediatric Male Subjects with Childhood Cerebral Adrenoleukodystrophy (CCALD) | Phase I/II, Open-Label, Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of NV1205 in Pediatric Male Subjects with Childhood Cerebral Adrenoleukodystrophy (CCALD) | Childhood Cerebral Adrenoleukodystrophy (CCALD);Therapeutic area: Diseases [C] - Hormonal diseases [C19] | Product Name: Sobetirome Product Code: NV1205 INN or Proposed INN: Sobetirome Other descriptive name: QTXEW2-04-AF, EW2, GC-1, QRX-431 | Neurov Acquisition LLC | NULL | Not Recruiting | Female: no Male: yes | 25 | Human pharmacology (Phase 1): yes Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | France;Argentina;Ukraine;Australia;Russian Federation;Chile;Colombia;United Kingdom | ||
| 3 | NCT01787578 (ClinicalTrials.gov) | April 2013 | 6/2/2013 | Safety and Pharmacodynamic Study of Sobetirome in X-Linked Adrenoleukodystrophy (X-ALD) | A Prospective Safety, Tolerance, Pharmacodynamics and Pharmacokinetics Study of Sobetirome in Male Subjects Diagnosed With X-linked Adrenoleukodystrophy (X-ALD) | X-Linked Adrenoleukodystrophy;Adrenomyeloneuropathy | Drug: Sobetirome | Thomas S. Scanlan | NULL | Withdrawn | 18 Years | 64 Years | Male | 0 | Phase 1 | United States |
| 4 | EUCTR2017-001684-21-FR (EUCTR) | 23/03/2018 | Phase 1, Open-Label, Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of NV1205 in Pediatric Male Subjects with Childhood Cerebral Adrenoleukodystrophy (CCALD) | Phase 1, Open-Label, Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of NV1205 in Pediatric Male Subjects with Childhood Cerebral Adrenoleukodystrophy (CCALD) | Childhood Cerebral Adrenoleukodystrophy (CCALD);Therapeutic area: Diseases [C] - Hormonal diseases [C19] | Product Name: Sobetirome Product Code: NV1205 INN or Proposed INN: Sobetirome Other descriptive name: QTXEW2-04-AF, EW2, GC-1, QRX-431 | NeuroVia, Inc. | NULL | NA | Female: no Male: yes | 25 | Human pharmacology (Phase 1): yes Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | France;Argentina;Ukraine;Australia;Russian Federation;Chile;Colombia;United Kingdom |